Net Income

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Palladyne AI launches its IQ 2.0 software, a low-code platform aiming to overhaul defense manufacturing in line with new government mandates.

Cineplex expands its free popcorn event to four days, a strategic move to leverage its loyalty program and combat the post-holiday attendance slump.

After a lengthy battle, a New York financier is cleared of all charges. Now, his lawsuit against FINRA and Capital Group challenges the system itself.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

West Red Lake Gold officially begins commercial production at its historic Madsen Mine, signaling a new era of gold output in the prolific Red Lake district.

The deepwater oil firm is refinancing its debt, extending maturities and tapping new markets to bolster its finances amid market volatility and analyst concerns.